Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319098 | 0.81 | — | — | |
| SCHEMBL473159 | 0.81 | MAOA (0.32) | — | |
| SCHEMBL3799009 | 0.81 | — | — | |
| SCHEMBL5139611 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL16188273 | 0.72 | BCL2L1 (0.33) | — | |
| SCHEMBL2942317 | 0.72 | CYP1A1 (0.34) | — | |
| SCHEMBL2951402 | 0.71 | PDE4A (0.36) | APOBEC3G | |
| Hydrochloric Acid SCHEMBL8585892 | 0.71 | ENPP2 (0.33) | — | |
| SCHEMBL5576021 | 0.70 | KDM4E (0.33) | — | |
| SCHEMBL5013668 | 0.70 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006034009-A2 | PURIFICATION OF BIOMOLECULES FROM CONTAMINATING INTACT NUCLEIC ACIDS | SIGMA-ALDRICH CO. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060068430-A1 | Purification of biomolecules from contaminating intact nucleic acids | SIGMA-ALDRICH CO. | 2006-03-30 | — | — | US | claimed |
| CN-115996754-A | Prophylactic and therapeutic immunotherapy of propionibacterium acnes | 免疫之源生物技术有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-7445641-B1 | Biomaterials modified with superoxide dismutase mimics | PHARMACIA CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070179124-A1 | Substituted Porphyrins | FRIDOVICH IRWIN | 2007-08-02 | — | — | US | disclosed |
| US-20060074062-A1 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2006-04-06 | — | — | US | disclosed |
| US-6916799-B2 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2005-07-12 | — | — | US | disclosed |
| WO-2005044149-A1 | MODIFIED HYALURONIC ACID POLYMERS | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| EP-1185312-B1 | BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS | MONSANTO CO (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1045851-B1 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1185312-A2 | BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS | MONSANTO COMPANY (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20020022215-A1 | Inactivation of small non-enveloped viruses and other microbial pathogens by porphyrins | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2002-02-21 | — | — | US | disclosed |
| WO-2002002153-A1 | INACTIVATION OF PATHOGENS BY PORPHYRINS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1045851-A4 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000072893-A2 | BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS | MONSANTO COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
| EP-1045851-A1 | SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY (US) | 2000-10-25 | — | — | EP | disclosed |
| US-6087493-A | ENZYME IHIBITORS | REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999023097-A1 | SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179124-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | PABPC1 3022/4885APOBEC3A 2352/4885EIF4H 3075/4885 |
| US-20060074062-A1 | Substituted porphyrins | PPOX, GPX4, PRDX5 | PABPC1 3022/4885APOBEC3A 2352/4885EIF4H 3075/4885 |
| US-20020022215-A1 | Inactivation of small non-enveloped viruses and other microbial pathogens by porphyrins | HMBS, PPOX, CD74 | PABPC1 1575/4885APOBEC3A 241/4885EIF4H 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.